Necitumumab

Necitumumab Property

form 

Liquid

color 

Colorless to light yellow

Hazard and Precautionary Statements (GHS)

Necitumumab Chemical Properties,Usage,Production

Uses

Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc[1].

Clinical Use

IgG1 monoclonal antibody:
Treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer

Drug interactions

Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use.

Metabolism

The elimination routes of necitumumab are only partially documented, and involve degradation to peptides after being internalised into its target cells, proteolysis within the liver or the reticuloendothelial system, as well as nonspecific endocytosis.

References

[1] Garnock-Jones KP. Necitumumab: First Global Approval. Drugs. 2016 Feb;76(2):283-9. DOI:10.1007/s40265-015-0537-0